Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Lung Cancer

  Free Subscription


02.03.2020

3 Ann Oncol
2 Ann Thorac Surg
11 BMC Cancer
1 Br J Cancer
1 Cancer Lett
2 Cancer Sci
3 Clin Cancer Res
5 Clin Lung Cancer
1 Clin Nucl Med
3 Eur J Cardiothorac Surg
5 J Cancer Res Clin Oncol
2 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 Lancet Respir Med
2 Lung Cancer
1 Lung Cancer (Auckl)
3 N Engl J Med
1 Oncogene
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. XIE Y
    Enhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
    Ann Oncol. 2019;30 Suppl 1:i13.
    PubMed     Text format    

  2. WANG M, Ma X
    Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
    Ann Oncol. 2019;30 Suppl 1:i10.
    PubMed     Text format    

  3. AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
    Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
    Ann Oncol. 2019;30 Suppl 1:i3.
    PubMed     Text format    


    Ann Thorac Surg

  4. WANG T, Deng J, She Y, Zhang L, et al
    Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small-Cell Lung Cancer.
    Ann Thorac Surg. 2020 Feb 19. pii: S0003-4975(20)30214.
    PubMed     Text format     Abstract available

  5. SHAHSAVARI S
    Methodological issue in prediction model for nodal disease among patients with lung cancer.
    Ann Thorac Surg. 2020 Feb 18. pii: S0003-4975(20)30209.
    PubMed     Text format    


    BMC Cancer

  6. DE HAAN R, van Werkhoven E, van den Heuvel MM, Peulen HMU, et al
    Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    BMC Cancer. 2019;19:901.
    PubMed     Text format     Abstract available

  7. CHANG YF, Lim KH, Chiang YW, Sie ZL, et al
    STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
    BMC Cancer. 2019;19:959.
    PubMed     Text format     Abstract available

  8. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Text format     Abstract available

  9. GOEBEL C, Louden CL, Mckenna R Jr, Onugha O, et al
    Blood test shows high accuracy in detecting stage I non-small cell lung cancer.
    BMC Cancer. 2020;20:137.
    PubMed     Text format     Abstract available

  10. WANG C, Wu Y, Shao J, Liu D, et al
    Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer.
    BMC Cancer. 2020;20:150.
    PubMed     Text format     Abstract available

  11. DUTTA P, Zhang L, Zhang H, Peng Q, et al
    Unphosphorylated STAT3 in heterochromatin formation and tumor suppression in lung cancer.
    BMC Cancer. 2020;20:145.
    PubMed     Text format     Abstract available

  12. ADACHI Y, Yanagimura N, Suzuki C, Ootani S, et al
    Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    BMC Cancer. 2020;20:156.
    PubMed     Text format     Abstract available

  13. PIAO L, Yang Z, Feng Y, Zhang C, et al
    LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma.
    BMC Cancer. 2019;19:898.
    PubMed     Text format     Abstract available

  14. HO GF, Chai CS, Alip A, Wahid MIA, et al
    Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    BMC Cancer. 2019;19:896.
    PubMed     Text format     Abstract available

  15. LI Y, Ge D, Gu J, Xu F, et al
    A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    BMC Cancer. 2019;19:886.
    PubMed     Text format     Abstract available

  16. LUO P, Yang X, Huang S, Feng S, et al
    Syntenin overexpression in human lung cancer tissue and serum is associated with poor prognosis.
    BMC Cancer. 2020;20:159.
    PubMed     Text format     Abstract available


    Br J Cancer

  17. KUEHL PJ, Tellez CS, Grimes MJ, March TH, et al
    5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.
    Br J Cancer. 2020 Feb 27. pii: 10.1038/s41416-020-0765.
    PubMed     Text format     Abstract available


    Cancer Lett

  18. ZHENG J, Zhang Y, Cai S, Dong L, et al
    MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
    Cancer Lett. 2020;476:129-139.
    PubMed     Text format     Abstract available


    Cancer Sci

  19. WANG W, Zhuang R, Ma H, Fang L, et al
    The diagnostic value of a 7-autoantibody panel and a nomogram for predicting the risk of non-small cell lung cancer.
    Cancer Sci. 2020 Feb 28. doi: 10.1111/cas.14371.
    PubMed     Text format     Abstract available

  20. SEKINE I, Shintani Y, Shukuya T, Takayama K, et al
    A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
    Cancer Sci. 2020 Feb 26. doi: 10.1111/cas.14368.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  21. DAGOGO-JACK I, Yoda S, Lennerz JK, Langenbucher A, et al
    MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
    Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-19-3906.
    PubMed     Text format     Abstract available

  22. AGGARWAL C, Thompson JC, Chien AL, Quinn KJ, et al
    Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer.
    Clin Cancer Res. 2020 Feb 26. pii: 1078-0432.CCR-19-3663.
    PubMed     Text format     Abstract available

  23. HOPKINS AM, Kichenadasse G, Garrett-Mayer E, Karapetis CS, et al
    Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab.
    Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-19-2968.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  24. TANAKA I, Morise M, Miyazawa A, Kodama Y, et al
    Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30011.
    PubMed     Text format     Abstract available

  25. AHMED T, Lycan T, Dothard A, Ehrlichman P, et al
    Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jan 23. pii: S1525-7304(20)30001.
    PubMed     Text format     Abstract available

  26. HANDA Y, Tsutani Y, Shiroma N, Kai Y, et al
    Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30013.
    PubMed     Text format     Abstract available

  27. RAJARAM R, Correa AM, Xu T, Nguyen QN, et al
    Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30009.
    PubMed     Text format     Abstract available

  28. PIZARRO G, Pinto MP, Munoz-Medel M, Cordova-Delgado M, et al
    Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30012.
    PubMed     Text format    


    Clin Nucl Med

  29. LI C, Tian Y, Shen Y, Wen B, et al
    Primary Leiomyosarcoma of the Bronchus: 18F-FDG PET/CT Findings.
    Clin Nucl Med. 2019 Oct 23. doi: 10.1097/RLU.0000000000002812.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  30. CASIRAGHI M, Bertolaccini L, Sedda G, Petrella F, et al
    Lung cancer surgery in oligometastatic patients: outcome and survival.
    Eur J Cardiothorac Surg. 2020 Feb 24. pii: 5753896. doi: 10.1093.
    PubMed     Text format     Abstract available

  31. DENG HY, Tang X
    Is less more for early-stage non-small-cell lung cancer? Current evidence for performing segmentectomy.
    Eur J Cardiothorac Surg. 2020 Feb 24. pii: 5753895. doi: 10.1093.
    PubMed     Text format    

  32. LOCOCO F, Chiappetta M, Cesario A, Margaritora S, et al
    Non-small-cell lung cancer with pathological complete response after induction therapy followed by surgical resection: which is the pattern of failure and which are the future perspectives?
    Eur J Cardiothorac Surg. 2020 Feb 27. pii: 5762453. doi: 10.1093.
    PubMed     Text format    


    J Cancer Res Clin Oncol

  33. SHU Z, Dong B, Shi L, Shen W, et al
    Stereotactic body radiotherapy for elderly patients (>/= 75 years) with early-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Feb 24. pii: 10.1007/s00432-020-03154.
    PubMed     Text format     Abstract available

  34. MUHAMMAD T, Sakhawat A, Khan AA, Huang H, et al
    Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Feb 22. pii: 10.1007/s00432-020-03157.
    PubMed     Text format     Abstract available

  35. LI Y, Qin Y
    Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2020;146:545-553.
    PubMed     Text format     Abstract available

  36. LIU DH, Ye ZH, Chen S, Sun XS, et al
    Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients.
    J Cancer Res Clin Oncol. 2020;146:801-807.
    PubMed     Text format     Abstract available

  37. QIN X, Wang H, Hu X, Gu X, et al
    Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information.
    J Cancer Res Clin Oncol. 2020;146:767-775.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  38. PREDINA JD, Newton AD, Corbett C, Shin M, et al
    Near-infrared intraoperative imaging for minimally invasive pulmonary metastasectomy for sarcomas.
    J Thorac Cardiovasc Surg. 2019;157:2061-2069.
    PubMed     Text format     Abstract available

  39. KAMEL MK, Lee B, Harrison S, Port JL, et al
    Do the surgical results in the National Lung Screening Trial reflect modern thoracic surgical practice?
    J Thorac Cardiovasc Surg. 2019;157:2038-2046.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  40. RAJADURAI P, How SH, Liam CK, Sachithanandan A, et al
    Lung Cancer in Malaysia.
    J Thorac Oncol. 2020;15:317-323.
    PubMed     Text format    


    Lancet Respir Med

  41. KIRBY T
    Lung cancer diagnosis can affect the whole family.
    Lancet Respir Med. 2020 Feb 25. pii: S2213-2600(20)30102.
    PubMed     Text format    


    Lung Cancer

  42. BOUSEMA JE, Heineman DJ, Dijkgraaf MGW, Annema JT, et al
    Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit - Surgery.
    Lung Cancer. 2020;142:51-58.
    PubMed     Text format     Abstract available

  43. ALEXANDER M, Pavlakis N, John T, O'Connell R, et al
    A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
    Lung Cancer. 2020;142:34-40.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  44. INOUE H, Okamoto I
    Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.
    Lung Cancer (Auckl). 2019;10:161-170.
    PubMed     Text format     Abstract available


    N Engl J Med

  45. KIM J, Shin SW
    Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;382:874.
    PubMed     Text format    

  46. BERSANELLI M, Tiseo M, Banna GL
    Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;382:874-875.
    PubMed     Text format    

  47. HELLMANN MD, Ramalingam SS
    Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2020;382:875.
    PubMed     Text format    


    Oncogene

  48. MORENO LEON L, Gautier M, Allan R, Ilie M, et al
    The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress.
    Oncogene. 2019;38:7146-7165.
    PubMed     Text format     Abstract available


    PLoS One

  49. KONERT T, Everitt S, La Fontaine MD, van de Kamer JB, et al
    Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?
    PLoS One. 2020;15:e0228793.
    PubMed     Text format     Abstract available

  50. CUBILLOS-ANGULO JM, Fukutani ER, Cruz LAB, Arriaga MB, et al
    Systems biology analysis of publicly available transcriptomic data reveals a critical link between AKR1B10 gene expression, smoking and occurrence of lung cancer.
    PLoS One. 2020;15:e0222552.
    PubMed     Text format     Abstract available

  51. LU G, Zhang Y
    Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p.
    PLoS One. 2020;15:e0229118.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: